pd-l1 in malignant pleural effusions · pd-l1 in malignant pleural effusions. alex soltermann....
TRANSCRIPT
![Page 1: PD-L1 in malignant pleural effusions · PD-L1 in malignant pleural effusions. Alex Soltermann. Department of Pathology and Molecular Pathology. Lung adenocarcinoma, cT2b, cN2, cM1a,](https://reader035.vdocuments.site/reader035/viewer/2022081408/605c5c27a2062745451b6582/html5/thumbnails/1.jpg)
PD-L1 in malignant pleural effusions
Alex Soltermann
Department of Pathology and Molecular Pathology
![Page 2: PD-L1 in malignant pleural effusions · PD-L1 in malignant pleural effusions. Alex Soltermann. Department of Pathology and Molecular Pathology. Lung adenocarcinoma, cT2b, cN2, cM1a,](https://reader035.vdocuments.site/reader035/viewer/2022081408/605c5c27a2062745451b6582/html5/thumbnails/2.jpg)
Lung adenocarcinoma, cT2b, cN2, cM1a, stage 4
PET-CT: centrally necrotic tumor right upper lung lobe, pleural infiltration, pleura carcinosis, massive effusion with subtotal atelectasis and eventual lymph node metastases hilar ipsilateral and mediastinal
Effusion cytologies (2 samples): TTF1+ lung adenocarcinoma
Mol Path: KRAS p.G12C exon 2
ECOG status 0 (fully active, able to carry on all pre-disease performance)
→ Cisplatin/Pemetrexed
Pat 68 yrs, 50 pys, 10/2015
![Page 3: PD-L1 in malignant pleural effusions · PD-L1 in malignant pleural effusions. Alex Soltermann. Department of Pathology and Molecular Pathology. Lung adenocarcinoma, cT2b, cN2, cM1a,](https://reader035.vdocuments.site/reader035/viewer/2022081408/605c5c27a2062745451b6582/html5/thumbnails/3.jpg)
• E1L3N antibody on Leica Bond automat
• Weak membranous immunoreactivity in >10% of tumor cells
• Category 3
01/2016 PD-L1 IHC
![Page 4: PD-L1 in malignant pleural effusions · PD-L1 in malignant pleural effusions. Alex Soltermann. Department of Pathology and Molecular Pathology. Lung adenocarcinoma, cT2b, cN2, cM1a,](https://reader035.vdocuments.site/reader035/viewer/2022081408/605c5c27a2062745451b6582/html5/thumbnails/4.jpg)
German PD-L1 harmonization trial
![Page 5: PD-L1 in malignant pleural effusions · PD-L1 in malignant pleural effusions. Alex Soltermann. Department of Pathology and Molecular Pathology. Lung adenocarcinoma, cT2b, cN2, cM1a,](https://reader035.vdocuments.site/reader035/viewer/2022081408/605c5c27a2062745451b6582/html5/thumbnails/5.jpg)
![Page 6: PD-L1 in malignant pleural effusions · PD-L1 in malignant pleural effusions. Alex Soltermann. Department of Pathology and Molecular Pathology. Lung adenocarcinoma, cT2b, cN2, cM1a,](https://reader035.vdocuments.site/reader035/viewer/2022081408/605c5c27a2062745451b6582/html5/thumbnails/6.jpg)
Tonsil, E1L3N, 100x
![Page 7: PD-L1 in malignant pleural effusions · PD-L1 in malignant pleural effusions. Alex Soltermann. Department of Pathology and Molecular Pathology. Lung adenocarcinoma, cT2b, cN2, cM1a,](https://reader035.vdocuments.site/reader035/viewer/2022081408/605c5c27a2062745451b6582/html5/thumbnails/7.jpg)
Effusion 1, E1L3N, 100x, Cat. 5
![Page 8: PD-L1 in malignant pleural effusions · PD-L1 in malignant pleural effusions. Alex Soltermann. Department of Pathology and Molecular Pathology. Lung adenocarcinoma, cT2b, cN2, cM1a,](https://reader035.vdocuments.site/reader035/viewer/2022081408/605c5c27a2062745451b6582/html5/thumbnails/8.jpg)
Effusion 2, E1L3N, 100x
![Page 9: PD-L1 in malignant pleural effusions · PD-L1 in malignant pleural effusions. Alex Soltermann. Department of Pathology and Molecular Pathology. Lung adenocarcinoma, cT2b, cN2, cM1a,](https://reader035.vdocuments.site/reader035/viewer/2022081408/605c5c27a2062745451b6582/html5/thumbnails/9.jpg)
Tonsil, SP263, 100x
![Page 10: PD-L1 in malignant pleural effusions · PD-L1 in malignant pleural effusions. Alex Soltermann. Department of Pathology and Molecular Pathology. Lung adenocarcinoma, cT2b, cN2, cM1a,](https://reader035.vdocuments.site/reader035/viewer/2022081408/605c5c27a2062745451b6582/html5/thumbnails/10.jpg)
Effusion 1, SP263, 100x
![Page 11: PD-L1 in malignant pleural effusions · PD-L1 in malignant pleural effusions. Alex Soltermann. Department of Pathology and Molecular Pathology. Lung adenocarcinoma, cT2b, cN2, cM1a,](https://reader035.vdocuments.site/reader035/viewer/2022081408/605c5c27a2062745451b6582/html5/thumbnails/11.jpg)
Effusion 2, SP263, 100x
![Page 12: PD-L1 in malignant pleural effusions · PD-L1 in malignant pleural effusions. Alex Soltermann. Department of Pathology and Molecular Pathology. Lung adenocarcinoma, cT2b, cN2, cM1a,](https://reader035.vdocuments.site/reader035/viewer/2022081408/605c5c27a2062745451b6582/html5/thumbnails/12.jpg)
Tonsil, DAKO 22C3 on Ventana
![Page 13: PD-L1 in malignant pleural effusions · PD-L1 in malignant pleural effusions. Alex Soltermann. Department of Pathology and Molecular Pathology. Lung adenocarcinoma, cT2b, cN2, cM1a,](https://reader035.vdocuments.site/reader035/viewer/2022081408/605c5c27a2062745451b6582/html5/thumbnails/13.jpg)
Effusion 2, DAKO 22C3 on Ventana
![Page 14: PD-L1 in malignant pleural effusions · PD-L1 in malignant pleural effusions. Alex Soltermann. Department of Pathology and Molecular Pathology. Lung adenocarcinoma, cT2b, cN2, cM1a,](https://reader035.vdocuments.site/reader035/viewer/2022081408/605c5c27a2062745451b6582/html5/thumbnails/14.jpg)